Antibody fragments structurally enable a drug‐discovery campaign on the cancer target Mcl‐1. Issue 11 (6th November 2019)

• Record Type: Journal Article
• Authors: Luptak, Jakub; Bista, Michal; Fisher, David; Flavell, Liz; Gao, Ning; Wickson, Kate; Kazmirski, Steven L.; Howard, Tina; Rawlins, Philip B.; Hargreaves, David
• Is Part Of: Acta crystallographica. Volume 75:Issue 11(2019)
• Page Start: 1003
• Page End: 1014
• Publication Date: 2019-11-06
• Subjects: Mcl‐1 -- scFv -- Fab -- drug design; X-ray crystallography -- Periodicals; Crystallography -- Periodicals; Molecular biology -- Periodicals; Molecular structure -- Periodicals; Biomolecules -- Structure -- Periodicals; Cytology -- Periodicals; Biomolecules -- Structure; Crystallography; Cytology; Molecular biology; Molecular structure; X-ray crystallography; Periodicals; 548
• DOI: 10.1107/S2059798319014116
• Languages: English
• ISSNs: 2059-7983

Abstract

Abstract : Mcl‐1 is an important cancer target for drug therapy, through which normal apoptosis may be restored by inhibiting its protective function. An scFv and a Fab have been used to generate an apo Mcl‐1 crystal system that is amenable to iterative structure‐guided drug design. Abstract : Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti‐apoptotic proteins of the Bcl‐2 (B‐cell lymphoma 2) family, including Mcl‐1 (myeloid cell leukaemia 1). This makes Mcl‐1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl‐1. Here, the discovery and biophysical properties of an anti‐Mcl‐1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl‐1 crystal system amenable to iterative structure‐guided drug design.